Literature DB >> 2850193

Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.

E Schneider1, S J Darkin, P A Lawson, L M Ching, R K Ralph, B C Baguley.   

Abstract

N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (NSC 601316) is a DNA intercalating experimental antitumour agent which is curative against the Lewis lung carcinoma in mice. Its action has been compared with amsacrine, its inactive isomer oAMSA, the solid tumour active derivative CI-921 (NSC 343499), a C-6 methylene chain-linked bisacridine (NSC 210733), 9-aminoacridine and quinacrine. All compounds inhibited the unknotting of phage P4 DNA by topoisomerase II in nuclear extracts prepared from L1210 cells. NSC 601316 inhibited growth of cultured L1210, P388, P/AMSA (P388 resistant to amsacrine) and P/ACTD (resistant to actinomycin D) cell lines at concentrations of 87, 150, 2020 and 150 nM respectively. A 1 h drug exposure to 0.85 microM NSC 601316 killed 50% of L1210 cells. L1210 cells treated for 1 h with NSC 601316 accumulated DNA breaks and protein-DNA cross-links. There was a good correlation between DNA breakage and cytotoxicity, but the relationship between drug concentration and number of protein-DNA cross-links was non-linear and differed from that of amsacrine and CI-921. There was also a positive correlation between the degree of cross-resistance of P/AMSA cells (which have altered topoisomerase II function) and ability to induce DNA breakage or protein-DNA complexes. The results suggest that topoisomerase II is the target of action of NSC 601316.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850193     DOI: 10.1016/0277-5379(88)90082-x

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  11 in total

Review 1.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

2.  Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration.

Authors:  Ya Jin; Zimei Wu; Caibin Li; Weisai Zhou; John P Shaw; Bruce C Baguley; Jianping Liu; Wenli Zhang
Journal:  Pharm Res       Date:  2018-01-04       Impact factor: 4.200

3.  Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.

Authors:  A Haldane; G J Finlay; J B Gavin; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Molecular modeling study of intercalation complexes of tricyclic carboxamides with d(CCGGCGCCGG)₂ and d(CGCGAATTCGCG)₂.

Authors:  Athanasia Varvaresou; Kriton Iakovou
Journal:  J Mol Model       Date:  2010-12-14       Impact factor: 1.810

5.  Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug.

Authors:  Wenli Zhang; Guangji Wang; James R Falconer; Bruce C Baguley; John P Shaw; Jianping Liu; Hongtao Xu; Esther See; Jianguo Sun; Jiye Aa; Zimei Wu
Journal:  Pharm Res       Date:  2014-10-30       Impact factor: 4.200

6.  Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.

Authors:  Christian Dittrich; Veronique Dieras; Pierre Kerbrat; Cornelis Punt; Roberto Sorio; Francesco Caponigro; Xavier Paoletti; Christine de Balincourt; Denis Lacombe; Pierre Fumoleau
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

7.  Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.

Authors:  A Haldane; K M Holdaway; G J Finlay; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.

Authors:  G J Finlay; E Marshall; J H Matthews; K D Paull; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide.

Authors:  B C Baguley; L Zhuang; E Marshall
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers.

Authors:  Reza Ehsanian; Carter Van Waes; Stephan M Feller
Journal:  Cell Commun Signal       Date:  2011-05-15       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.